ID

35327

Descripción

Study ID: 101222 Clinical Study ID: 101222 Study Title: Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine (KFT) Trade Name:Zilbrix/Hib Study Indication: Diphtheria; Haemophilus influenzae type b; Hepatitis B; Tetanus; Whole Cell Pertussis

Palabras clave

Versiones (2)
  1. 25/2/19 25/2/19 -
  2. 28/2/19 28/2/19 -
Titular de derechos de autor

GSK group of companies

Subido en

28 de febrero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Immunogenicity of TPw-HBV/Hib Kft. Vaccine in healthy infants - 101222

Inglés

Visit 1

1 formularios  
  1. StudyEvent: ODM
    1. Visit 1
Administrative data
Descripción

Administrative data

Visit Number
Descripción

Visit Number

Tipo de datos

integer

Subject Number
Descripción

Subject Number

Tipo de datos

integer

ELIMINATION CRITERIA
Descripción

ELIMINATION CRITERIA

Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the combined DTPw-HepB vaccine or DTPw-HepB/Hib vaccine, with the exception of oral poliovirus vaccine (OPV).
Descripción

The following criteria should be checked at Visit 2. If any become applicable during the study, it will not require withdrawal of the subject from the study but does determine a subject’s evaluability in the according-to-protocol analysis (ATP) analysis

Tipo de datos

boolean

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Descripción

EliminationCriteriaConcomitantMedication

Tipo de datos

boolean

Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Descripción

EliminationCriteriaImmunosuppressants

Tipo de datos

boolean

Hepatitis B vaccine received after the first 72 hours of life.
Descripción

EliminationCriteriaPriorVaccination

Tipo de datos

boolean

Bacille Calmette-Guérin (BCG) vaccine given after the first 2 weeks of life.
Descripción

EliminationCriteriaBacilleCalmette-Guérin

Tipo de datos

boolean

Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae or hepatitis B (except if indicated in the group allocation).
Descripción

EliminationCriteriaPreviousVaccination

Tipo de datos

boolean

History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B or Hib diseases.
Descripción

EliminationCriteriaHistoryDiphteria

Tipo de datos

boolean

Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
Descripción

EliminationCriteriaImmunodeficientCondition

Tipo de datos

boolean

History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Descripción

EliminationCriteriaAllergies

Tipo de datos

boolean

Administration of immunoglobulins and/ or any blood products during the study period.
Descripción

EliminationCriteriaImmunoglobulinsAdministration

Tipo de datos

boolean

Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period.
Descripción

The following criteria should be checked at Visits 3, 4 and 5. If any become applicable during the study, it will not require withdrawal of the subject from the study but does determine a subject’s evaluability in ATP analysis.

Tipo de datos

boolean

Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
Descripción

EliminationCriteriaChronicImmunosuppressantsAdministration

Tipo de datos

boolean

Planned administration/ administration of a vaccine not foreseen by the study protocol during the period from 30 days before each dose of vaccine and ending 30 after the last dose of vaccine, with the exception of OPV.
Descripción

EliminationCriteriaPlannedConcomitantVaccineAdministration

Tipo de datos

boolean

Administration of immunoglobulins and/or any blood products during the study period.
Descripción

EliminationCriteriaImmunoglobulinsAdministration

Tipo de datos

boolean

Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing required at study entry).
Descripción

EliminationCriteriaImmunodeficientCondition

Tipo de datos

boolean

CONTRAINDICATIONS TO SUBSEQUENT VACCINATION
Descripción

CONTRAINDICATIONS TO SUBSEQUENT VACCINATION

Anaphylactic reaction following the administration of vaccines.
Descripción

The following adverse events (AEs) constitute absolute contraindications to further administration of the study vaccines; if any of these AEs occur during the study, the subject must not receive additional doses of vaccine but may continue other study procedures at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE

Tipo de datos

boolean

Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines
Descripción

ContraindicationsHypersensitivity

Tipo de datos

boolean

Encephalopathy (not due to another identifiable cause).
Descripción

This is defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination, and generally consisting of major alterations in consciousness, unresponsiveness, generalized or focal seizures that persist more than a few hours, with failure to recover within 24 hours. Even though causation by DTP vaccine cannot be established, no subsequent doses of pertussis vaccine should be given. In these circumstances the vaccination course should be continued with DT and HB vaccines.

Tipo de datos

boolean

Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature < 37.5 °C or rectal temperature < 38 °C.
Descripción

The following AEs constitute contraindications to administration of the study vaccines at that point in time; if any one of these AEs occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.

Tipo de datos

boolean

Axillary or oral temperature = 37.5 °C or Rectal temperature = 38 °C at the time of vaccination.
Descripción

ContraindicationsTemperature

Tipo de datos

boolean

Precautions:
Descripción

Precautions:

Fever = 40.0 °C (preferable axillary temperature or oral temperature) within 48 hours of vaccination, not due to another identifiable cause.
Descripción

If any of the following events occur in temporal relation to receipt of study vaccines, the decision to give subsequent doses of vaccine containing the pertussis component should be carefully considered.

Tipo de datos

boolean

Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
Descripción

PrecautionsShock

Tipo de datos

boolean

Persistent crying lasting = 3 hours, occurring within 48 hours of vaccination
Descripción

PrecautionsCrying

Tipo de datos

boolean

Convulsions with or without fever, occurring within 3 days of vaccination.
Descripción

PrecautionsConvulsions

Tipo de datos

boolean

Additional Precautions:
Descripción

AdditionalPrecautions

Tipo de datos

text

INFORMED CONSENT
Descripción

INFORMED CONSENT

I certify that Informed Consent has been obtained prior to any study procedure.
Descripción

I certify that Informed Consent has been obtained prior to any study procedure.

Tipo de datos

boolean

Informed Consent Date :
Descripción

Informed Consent Date :

Tipo de datos

date

DEMOGRAPHICS
Descripción

DEMOGRAPHICS

Center number :
Descripción

CenterNumber

Tipo de datos

integer

Date of birth :
Descripción

BirthDate

Tipo de datos

date

Gender :
Descripción

Gender :

Tipo de datos

text

Race :
Descripción

Race

Tipo de datos

text

If Other, please specify
Descripción

OtherRace

Tipo de datos

text

ELIGIBILITY CHECK
Descripción

ELIGIBILITY CHECK

Did the subject meet all the entry criteria?
Descripción

Do not enter the subject into the study if he/she failed any inclusion or exclusion criteria below.

Tipo de datos

boolean

INCLUSION CRITERIA
Descripción

INCLUSION CRITERIA

Tick the boxes corresponding to any of the inclusion criteria the subject failed
Descripción

InclusionCriteriaFailed

Tipo de datos

text

EXCLUSION CRITERIA
Descripción

EXCLUSION CRITERIA

Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
Descripción

ExclusionCriteria

Tipo de datos

text

RANDOMISATION / TREATMENT ALLOCATION
Descripción

RANDOMISATION / TREATMENT ALLOCATION

Record treatment number
Descripción

TreatmentNumber

Tipo de datos

integer

GROUP HBV AT BIRTH
Descripción

GROUP HBV AT BIRTH

Has the Engerix™-B vaccine been administered at birth ?
Descripción

ENGERIX™-B VACCINE Only for subjects in the HBV+DTPw-HBV/Hib Kft group

Tipo de datos

boolean

Volver a la parte superior de la página

Similar models

Visit 1

1 formularios
  1. StudyEvent: ODM
    1. Visit 1
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Administrative data
Visit Number
Item
Visit Number
integer
Subject Number
Item
Subject Number
integer
Item Group
ELIMINATION CRITERIA
Planned administration/administration of a vaccine not foreseen by the study protocol
Item
Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the combined DTPw-HepB vaccine or DTPw-HepB/Hib vaccine, with the exception of oral poliovirus vaccine (OPV).
boolean
EliminationCriteriaConcomitantMedication
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
boolean
EliminationCriteriaImmunosuppressants
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
EliminationCriteriaPriorVaccination
Item
Hepatitis B vaccine received after the first 72 hours of life.
boolean
EliminationCriteriaBacilleCalmette-Guérin
Item
Bacille Calmette-Guérin (BCG) vaccine given after the first 2 weeks of life.
boolean
EliminationCriteriaPreviousVaccination
Item
Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae or hepatitis B (except if indicated in the group allocation).
boolean
EliminationCriteriaHistoryDiphteria
Item
History of or known exposure to diphtheria, tetanus, pertussis, hepatitis B or Hib diseases.
boolean
EliminationCriteriaImmunodeficientCondition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing is required at study entry).
boolean
EliminationCriteriaAllergies
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
boolean
EliminationCriteriaImmunoglobulinsAdministration
Item
Administration of immunoglobulins and/ or any blood products during the study period.
boolean
EliminationCriteriaConcomitantVaccines
Item
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period.
boolean
EliminationCriteriaChronicImmunosuppressantsAdministration
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immunomodifying drugs during the study period. (For corticostreoids, this will mean prednisone, or equivalent, = 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
boolean
EliminationCriteriaPlannedConcomitantVaccineAdministration
Item
Planned administration/ administration of a vaccine not foreseen by the study protocol during the period from 30 days before each dose of vaccine and ending 30 after the last dose of vaccine, with the exception of OPV.
boolean
EliminationCriteriaImmunoglobulinsAdministration
Item
Administration of immunoglobulins and/or any blood products during the study period.
boolean
EliminationCriteriaImmunodeficientCondition
Item
Any confirmed immunodeficient condition, based on medical history and physical examination (no laboratory testing required at study entry).
boolean
Item Group
CONTRAINDICATIONS TO SUBSEQUENT VACCINATION
ContraindicationsAnaphylacticReaction
Item
Anaphylactic reaction following the administration of vaccines.
boolean
ContraindicationsHypersensitivity
Item
Known hypersensitivity to any component of the vaccine, or subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, hepatitis B or Hib vaccines
boolean
ContraindicationsEncephalopathy
Item
Encephalopathy (not due to another identifiable cause).
boolean
ContraindicationsDisease
Item
Acute disease at the time of vaccination. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature < 37.5 °C or rectal temperature < 38 °C.
boolean
ContraindicationsTemperature
Item
Axillary or oral temperature = 37.5 °C or Rectal temperature = 38 °C at the time of vaccination.
boolean
Item Group
Precautions:
PrecautionsFever
Item
Fever = 40.0 °C (preferable axillary temperature or oral temperature) within 48 hours of vaccination, not due to another identifiable cause.
boolean
PrecautionsShock
Item
Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
boolean
PrecautionsCrying
Item
Persistent crying lasting = 3 hours, occurring within 48 hours of vaccination
boolean
PrecautionsConvulsions
Item
Convulsions with or without fever, occurring within 3 days of vaccination.
boolean
Item
Additional Precautions:
text
AdditionalPrecautions
Code List
Additional Precautions:
CL Item
A history of febrile convulsions, a family history of convulsions, a family history of Sudden Infant Death (1)
CL Item
Syndrome (SIDS) and a family history of an adverse event following Tritanrix™-HepB vaccination do not (Syndrome (SIDS) and a family history of an adverse event following Tritanrix™-HepB vaccination do not)
CL Item
constitute contraindications. (constitute contraindications.)
CL Item
As with all injectable vaccines, appropriate medical treatment should always be readily available in case of (2)
CL Item
anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should (anaphylactic reactions following the administration of the vaccine. For this reason, the vaccinee should)
CL Item
remain under medical supervision for 30 minutes after vaccination. (remain under medical supervision for 30 minutes after vaccination.)
CL Item
DTPw-HBV should be administered with caution to subjects with thrombocytopenia or a bleeding disorder (3)
CL Item
since bleeding may occur following an intramuscular administration to these subjects. (since bleeding may occur following an intramuscular administration to these subjects.)
CL Item
DTPw-HBV should under no circumstances be administered intravenously. (DTPw-HBV should under no circumstances be administered intravenously.)
Item Group
INFORMED CONSENT
I certify that Informed Consent has been obtained prior to any study procedure.
Item
I certify that Informed Consent has been obtained prior to any study procedure.
boolean
Informed Consent Date :
Item
Informed Consent Date :
date
Item Group
DEMOGRAPHICS
CenterNumber
Item
Center number :
integer
BirthDate
Item
Date of birth :
date
Item
Gender :
text
Gender :
Code List
Gender :
CL Item
Male (1)
CL Item
Female (2)
Item
Race :
text
Race
Code List
Race :
CL Item
Black (1)
CL Item
Arabic/North African (2)
CL Item
White/Caucasian (3)
CL Item
East & South East Asian (4)
CL Item
South Asian (5)
CL Item
American Hispanic (6)
CL Item
Japanese (7)
CL Item
Other (8)
OtherRace
Item
If Other, please specify
text
Item Group
ELIGIBILITY CHECK
EligibilityCheckQuestion
Item
Did the subject meet all the entry criteria?
boolean
Item Group
INCLUSION CRITERIA
Item
Tick the boxes corresponding to any of the inclusion criteria the subject failed
text
InclusionCriteriaFailed
Code List
Tick the boxes corresponding to any of the inclusion criteria the subject failed
CL Item
Born to a mother known to be seronegative for HBsAg (documented laboratory result of HBsAgassay from a maternal blood sample is available). (1)
CL Item
Written informed consent obtained from the parent or guardian of the subject. (2)
CL Item
Free of obvious health problems as established by medical history and clinical examination (3)
CL Item
before entering into the study. (before entering into the study.)
CL Item
Born after a normal gestation period (between 36 and 42 weeks). (4)
CL Item
A male or female less than or equal to 3 days (72 hours) of age at the time of the birth dose of (5)
CL Item
Hepatitis B vaccination, if indicated for the group. (Hepatitis B vaccination, if indicated for the group.)
CL Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) since birth, or planned use during the study period. (6)
Item Group
EXCLUSION CRITERIA
Item
Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
text
ExclusionCriteria
Code List
Tick the box corresponding to any of the exclusion criteria that disqualified the subject from entry.
CL Item
Use of any investigational or non-registered product (drug or vaccine) other than the study (1)
CL Item
vaccine(s) since birth, or planned use during the study period. (vaccine(s) since birth, or planned use during the study period.)
CL Item
Any confirmed immunodeficient condition, based on medical history and physical (2)
CL Item
examination (no laboratory testing is required at study entry). (examination (no laboratory testing is required at study entry).)
CL Item
A family history of congenital or hereditary immunodeficiency. (3)
CL Item
Major congenital defects or serious chronic illness. (4)
CL Item
History of any neurologic disorders or seizures. (5)
CL Item
Administration of immunoglobulins and/or any blood products since birth or planned (6)
CL Item
administration during the study period. (administration during the study period.)
CL Item
Acute disease at the time of enrolment. (Acute disease is defined as the presence of a (7)
CL Item
moderate or severe illness with or without fever. All vaccines can be administered to (moderate or severe illness with or without fever. All vaccines can be administered to)
CL Item
persons with a minor illness such as diarrhea, mild upper respiratory infection with or without (persons with a minor illness such as diarrhea, mild upper respiratory infection with or without)
CL Item
low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C). (low-grade febrile illness, i.e., axillary temperature < 37.5 °C or rectal temperature < 38 °C).)
CL Item
Other conditions which in the opinion of the investigator may potentially interfere with (8)
CL Item
interpretation of study outcomes. (interpretation of study outcomes.)
CL Item
Hepatitis B vaccination given at birth outside the study. (9)
Item Group
RANDOMISATION / TREATMENT ALLOCATION
TreatmentNumber
Item
Record treatment number
integer
Item Group
GROUP HBV AT BIRTH
VaccinationAtBirth
Item
Has the Engerix™-B vaccine been administered at birth ?
boolean
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial